Ventyx Biosciences, Inc. (VTYX)
Largest Insider Buys in Sector
VTYX Stock Price History Chart
VTYX Stock Performance
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Insider Activity of Ventyx Biosciences, Inc.
Over the last 12 months, insiders at Ventyx Biosciences, Inc. have bought $0 and sold $39.6M worth of Ventyx Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Ventyx Biosciences, Inc. have bought $40M and sold $53.31M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,250,000 shares for transaction amount of $20M was made by Cormorant Asset Management, LP () on 2021‑10‑25.
List of Insider Buy and Sell Transactions, Ventyx Biosciences, Inc.
| 2024-04-02 | Sale | Mohan Raju | CEO AND PRESIDENT | 4,312 0.0075% | $5.40 | $23,299 | -14.89% | |
| 2024-04-02 | Sale | Krueger Christopher W | CHIEF BUSINESS OFFICER | 1,651 0.0029% | $5.40 | $8,921 | -14.89% | |
| 2024-04-02 | Sale | Nuss John | CHIEF SCIENTIFIC OFFICER | 1,651 0.0029% | $5.40 | $8,921 | -14.89% | |
| 2024-04-02 | Sale | Auster Martin | CHIEF FINANCIAL OFFICER | 1,405 0.0024% | $5.40 | $7,592 | -14.89% | |
| 2023-12-20 | Sale | Mohan Raju | CEO and President | 58,860 0.1014% | $2.12 | $124,660 | +109.29% | |
| 2023-12-20 | Sale | Krueger Christopher W | Chief Business Officer | 5,293 0.0091% | $2.12 | $11,210 | +109.29% | |
| 2023-12-20 | Sale | Nuss John | Chief Scientific Officer | 17,628 0.0304% | $2.12 | $37,334 | +109.29% | |
| 2023-10-09 | Sale | Subramaniam Somu | 49,152 0.0835% | $30.03 | $1.48M | -86.30% | ||
| 2023-10-09 | Sale | NSV Partners III LP | 10 percent owner | 49,152 0.0835% | $30.03 | $1.48M | -86.30% | |
| 2023-10-05 | Sale | Mohan Raju | Chief Executive Officer | 30,000 0.0476% | $29.11 | $873,231 | -86.01% | |
| 2023-10-03 | Sale | Krueger Christopher W | Chief Business Officer | 15,000 0.0245% | $29.98 | $449,699 | -86.16% | |
| 2023-10-03 | Sale | Nuss John | Chief Scientific Officer | 10,000 0.0163% | $29.99 | $299,933 | -86.16% | |
| 2023-09-18 | Sale | Subramaniam Somu | 56,665 0.0964% | $37.81 | $2.14M | -88.43% | ||
| 2023-09-18 | Sale | NSV Partners III LP | 10 percent owner | 56,665 0.0964% | $37.81 | $2.14M | -88.43% | |
| 2023-09-05 | Sale | Mohan Raju | Chief Executive Officer | 30,000 0.0515% | $32.61 | $978,343 | -86.12% | |
| 2023-09-05 | Sale | Krueger Christopher W | Chief Business Officer | 15,000 0.0258% | $32.61 | $489,109 | -86.12% | |
| 2023-09-05 | Sale | Nuss John | Chief Scientific Officer | 10,000 0.0172% | $32.60 | $325,960 | -86.12% | |
| 2023-09-05 | Sale | Auster Martin | Chief Financial Officer | 26,472 0.0455% | $32.61 | $863,334 | -86.12% | |
| 2023-08-31 | Sale | Sandborn William J. | See Remarks | 11,900 0.0203% | $33.64 | $400,354 | -86.43% | |
| 2023-08-08 | Sale | Sandborn William J. | See Remarks | 3,494 0.0059% | $32.86 | $114,810 | -85.66% |
Insider Historical Profitability
| Subramaniam Somu | 8439635 14.3113% | $2.32 | 0 | 22 | ||
| NSV Partners III LP | 10 percent owner | 8439635 14.3113% | $2.32 | 0 | 22 | |
| Mohan Raju | CEO and President | 1578250 2.6635% | $2.32 | 0 | 14 | |
| Krueger Christopher W | Chief Business Officer | 284999 0.4784% | $2.32 | 0 | 14 | |
| Nuss John | Chief Scientific Officer | 264998 0.4445% | $2.32 | 0 | 13 | |
| Sandborn William J. | See Remarks | 48389 0.0821% | $2.32 | 0 | 10 | |
| Auster Martin | Chief Financial Officer | 24303 0.0359% | $2.32 | 0 | 8 | |
| Royston Aaron | 3997269 6.7783% | $2.32 | 1 | 0 | <0.0001% | |
| venBio Global Strategic Fund III, L.P. | 10 percent owner | 3997269 6.7783% | $2.32 | 1 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 1410303 2.3915% | $2.32 | 1 | 0 | <0.0001% | |
| Gujrathi Sheila | director | 0 0% | $2.32 | 0 | 1 | |
| White William Richard | director | 0 0% | $2.32 | 0 | 1 |
Institutional Investor Ownership
| Citadel Advisors LLC | $31.8M | 8.36 | 5.89M | +38.09% | +$8.77M | 0.02 | |
| BlackRock | $20.61M | 5.32 | 3.75M | -1.77% | -$370,909.01 | <0.0001 | |
| The Vanguard Group | $20.38M | 5.26 | 3.71M | -0.97% | -$200,491.50 | <0.0001 | |
| Deerfield Management | $19.48M | 5.02 | 3.54M | New | +$19.48M | 0.38 | |
| Farallon Capital | $17.43M | 4.5 | 3.17M | New | +$17.43M | 0.12 | |
| Tang Capital Management, LLC | $17.05M | 4.4 | 3.1M | +55% | +$6.05M | 0.07 | |
| Cormorant Asset Management Lp | $14.9M | 3.84 | 2.71M | New | +$14.9M | 0.71 | |
| Point72 Asset Management | $13.92M | 3.59 | 2.53M | New | +$13.92M | 0.03 | |
| Schonfeld Group | $13.02M | 3.36 | 2.37M | +1,108.89% | +$11.94M | 0.09 | |
| Capital International Investors | $12.95M | 3.34 | 2.35M | 0% | +$0 | <0.01 | |
| Redmile Group | $11.9M | 3.07 | 2.16M | +944.45% | +$10.76M | 0.44 | |
| OrbiMed | $10.29M | 2.65 | 1.87M | New | +$10.29M | 0.21 | |
| Goldman Sachs | $9.26M | 2.39 | 1.68M | +23.58% | +$1.77M | <0.01 | |
| Octagon Capital Advisors LP | $8.26M | 2.13 | 1.5M | New | +$8.26M | 1.08 | |
| Morgan Stanley | $7.34M | 1.89 | 1.33M | -30.32% | -$3.19M | <0.01 | |
| Opaleye Management Inc | $7.07M | 1.82 | 1.28M | +12.72% | +$797,500.00 | 1.12 | |
| Adage Capital Partners Gp L L C | $6.96M | 1.79 | 1.27M | +110.84% | +$3.66M | 0.01 | |
| Parkman Healthcare Partners Llc | $6.64M | 1.71 | 1.21M | New | +$6.64M | 0.82 | |
| Geode Capital Management | $6.09M | 1.57 | 1.11M | +7.92% | +$446,611.68 | <0.01 | |
| Sphera Fund | $5.46M | 1.41 | 992,749 | +451.53% | +$4.47M | 0.9 | |
| JPMorgan Chase | $5.24M | 1.35 | 953,473 | +763.87% | +$4.64M | <0.0001 | |
| State Street | $5.1M | 1.31 | 926,589 | -6.45% | -$351,087.03 | <0.0001 | |
| Tcg Crossover Management Llc | $4.49M | 1.16 | 815,724 | 0% | +$0 | 0.01 | |
| First Light Asset Management | $3.44M | 0.89 | 624,842 | New | +$3.44M | 0.27 | |
| Ikarian Capital LLC | $2.79M | 0.72 | 507,647 | +8,483.82% | +$2.76M | 0.8 | |
| Connor Clark & Lunn Investment Management Ltd | $2.62M | 0.68 | 475,619 | +106.21% | +$1.35M | 0.01 | |
| Millennium Management LLC | $2.6M | 0.67 | 472,666 | -75.57% | -$8.04M | <0.01 | |
| Macquarie Group | $2.37M | 0.61 | 430,000 | New | +$2.37M | <0.01 | |
| Qiming U S Ventures Management Llc | $2.27M | 0.59 | 412,225 | -39.94% | -$1.51M | 2.53 | |
| Northern Trust | $2.18M | 0.56 | 397,077 | -12.48% | -$311,509.21 | <0.0001 | |
| Charles Schwab | $2.12M | 0.55 | 384,883 | +19.09% | +$339,311.58 | <0.0001 | |
| Fidelity Investments | $2.08M | 0.54 | 378,621 | +444.91% | +$1.7M | <0.0001 | |
| Sio Capital Management LLC | $2.08M | 0.54 | 378,000 | New | +$2.08M | 0.74 | |
| Walleye Capital | $1.74M | 0.45 | 315,978 | +449.57% | +$1.42M | 0.01 | |
| Bank of America | $1.67M | 0.43 | 303,240 | +484.46% | +$1.38M | <0.0001 | |
| D. E. Shaw & Co. | $1.08M | 0.28 | 196,114 | -61.89% | -$1.75M | <0.01 | |
| Lighthouse Investment Partners, LLC | $932,239.00 | 0.24 | 169,498 | New | +$932,239.00 | 0.06 | |
| BNY Mellon | $800,850.00 | 0.21 | 145,609 | -6.61% | -$56,661.04 | <0.0001 | |
| Boothbay Fund Management LLC | $797,511.00 | 0.21 | 145,002 | New | +$797,511.00 | 0.03 | |
| Invesco | $797,715.00 | 0.21 | 145,039 | +497.9% | +$664,295.92 | <0.0001 | |
| Nuveen | $737,243.00 | 0.19 | 134,044 | -28.98% | -$300,866.91 | <0.0001 | |
| Ubs Oconnor Llc | $737,000.00 | 0.19 | 134,000 | New | +$737,000.00 | 0.06 | |
| Jane Street Capital | $668,789.00 | 0.17 | 121,598 | -73.69% | -$1.87M | <0.01 | |
| PDT Partners | $662,761.00 | 0.17 | 120,502 | New | +$662,761.00 | 0.05 | |
| OMERS | $663,850.00 | 0.17 | 120,700 | New | +$663,850.00 | 0.01 | |
| Susquehanna International Group | $646,679.00 | 0.17 | 117,578 | -63.64% | -$1.13M | <0.01 | |
| Mariner Llc | $639,452.00 | 0.17 | 116,264 | -21.17% | -$171,743.00 | <0.01 | |
| Voya Investment Management LLC | $611,430.00 | 0.16 | 111,169 | +486.58% | +$507,193.91 | <0.01 | |
| Hightower Advisors | $537,000.00 | 0.14 | 97,534 | -15.98% | -$102,170.62 | <0.01 | |
| Two Sigma Advisers LP | $486,200.00 | 0.13 | 88,400 | -92.03% | -$5.61M | <0.01 |